Does the media favor RLAY or BBIO?

In the previous week, Relay Therapeutics had 9 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for Relay Therapeutics and 1 mentions for BridgeBio Pharma. Relay Therapeutics' average media sentiment score of 0.21 beat BridgeBio Pharma's score of 0.13 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RLAY or RDY?

Relay Therapeutics presently has a consensus price target of $23.73, suggesting a potential upside of 20.87%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor RLAY or AXSM?

In the previous week, Relay Therapeutics had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 10 mentions for Relay Therapeutics and 7 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.41 beat Relay Therapeutics' score of 0.21 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ELAN or RLAY?

In the previous week, Relay Therapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Relay Therapeutics and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Relay Therapeutics' score of 0.21 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARWR or RLAY?

In the previous week, Relay Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 10 mentions for Relay Therapeutics and 9 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.04 beat Relay Therapeutics' score of 0.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Relay Therapeutics (RLAY) Competitors

$19.63 -0.11 (-0.56%)

Closing price 07/8/2026 04:00 PM Eastern

Extended Trading

$19.45 -0.18 (-0.89%)

As of 07/8/2026 07:43 PM Eastern

Compare

RLAY vs. BBIO, RDY, AXSM, ELAN, and ARWR

Should you buy Relay Therapeutics stock or one of its competitors? MarketBeat compares Relay Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relay Therapeutics include BridgeBio Pharma (BBIO), Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Relay Therapeutics compare to BridgeBio Pharma?

Relay Therapeutics (NASDAQ:RLAY) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Relay Therapeutics presently has a consensus price target of $23.73, suggesting a potential upside of 20.87%. BridgeBio Pharma has a consensus price target of $92.90, suggesting a potential upside of 18.60%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Relay Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
BridgeBio Pharma	-124.42%	N/A	-65.81%

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Relay Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Relay Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	245.01	-$276.48M	-$1.57	N/A
BridgeBio Pharma	$502.08M	30.56	-$724.93M	-$3.74	N/A

In the previous week, Relay Therapeutics had 9 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for Relay Therapeutics and 1 mentions for BridgeBio Pharma. Relay Therapeutics' average media sentiment score of 0.21 beat BridgeBio Pharma's score of 0.13 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats BridgeBio Pharma on 12 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Relay Therapeutics (NASDAQ:RLAY) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Relay Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	245.01	-$276.48M	-$1.57	N/A
Dr. Reddy's Laboratories	$3.58B	3.30	$456M	$0.58	24.41

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Relay Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Relay Therapeutics presently has a consensus price target of $23.73, suggesting a potential upside of 20.87%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Relay Therapeutics had 10 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Relay Therapeutics and 0 mentions for Dr. Reddy's Laboratories. Relay Therapeutics' average media sentiment score of 0.21 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Dr. Reddy's Laboratories	Neutral

Summary

Relay Therapeutics beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Axsome Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Relay Therapeutics had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 10 mentions for Relay Therapeutics and 7 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.41 beat Relay Therapeutics' score of 0.21 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has higher revenue and earnings than Relay Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	245.01	-$276.48M	-$1.57	N/A
Axsome Therapeutics	$638.50M	19.79	-$183.17M	-$3.73	N/A

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Relay Therapeutics currently has a consensus target price of $23.73, indicating a potential upside of 20.87%. Axsome Therapeutics has a consensus target price of $259.05, indicating a potential upside of 5.49%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Relay Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Relay Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Relay Therapeutics' return on equity of -43.94% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Relay Therapeutics beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Elanco Animal Health has higher revenue and earnings than Relay Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.62	-$232M	-$0.50	N/A
Relay Therapeutics	$15.35M	245.01	-$276.48M	-$1.57	N/A

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $28.55, suggesting a potential upside of 15.58%. Relay Therapeutics has a consensus target price of $23.73, suggesting a potential upside of 20.87%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Relay Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Relay Therapeutics	N/A	-43.94%	-40.11%

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Relay Therapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Relay Therapeutics and 4 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.16 beat Relay Therapeutics' score of 0.21 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elanco Animal Health and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Arrowhead Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Arrowhead Pharmaceuticals presently has a consensus target price of $87.27, suggesting a potential upside of 1.79%. Relay Therapeutics has a consensus target price of $23.73, suggesting a potential upside of 20.87%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Relay Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Relay Therapeutics' return on equity of -43.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Relay Therapeutics	N/A	-43.94%	-40.11%

In the previous week, Relay Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 10 mentions for Relay Therapeutics and 9 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.04 beat Relay Therapeutics' score of 0.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.56	-$1.63M	-$2.15	N/A
Relay Therapeutics	$15.35M	245.01	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Arrowhead Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.78B	$3.15B	$7.00B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	7.39%
P/E Ratio	-12.50	20.08	27.14	24.24
Price / Sales	245.01	367.14	534.05	96.53
Price / Cash	N/A	57.46	49.24	56.96
Price / Book	6.00	4.42	10.83	6.38
Net Income	-$276.48M	$64.65M	$3.56B	$331.19M
7 Day Performance	5.25%	-0.15%	-0.01%	-1.32%
1 Month Performance	39.32%	6.88%	5.28%	1.27%
1 Year Performance	415.22%	25.05%	30.31%	20.73%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	2.6581 of 5 stars	$19.63 -0.6%	$23.73 +20.9%	+446.8%	$3.78B	$15.35M	N/A	330	News Coverage Analyst Forecast Insider Trade
BBIO BridgeBio Pharma	2.6857 of 5 stars	$72.01 +2.5%	$92.90 +29.0%	+81.4%	$13.76B	$502.08M	N/A	400
RDY Dr. Reddy's Laboratories	1.3731 of 5 stars	$14.88 -3.3%	N/A	-4.2%	$12.84B	$3.58B	25.65	27,527	High Trading Volume
AXSM Axsome Therapeutics	1.9444 of 5 stars	$241.12 -0.2%	$258.95 +7.4%	+126.5%	$12.44B	$638.50M	N/A	380	Analyst Forecast
ELAN Elanco Animal Health	3.7055 of 5 stars	$24.76 +0.8%	$28.55 +15.3%	+67.4%	$12.27B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. BBIO, RDY, AXSM, ELAN, and ARWR

How does Relay Therapeutics compare to BridgeBio Pharma?

Summary

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Relay Therapeutics compare to Axsome Therapeutics?

Summary

How does Relay Therapeutics compare to Elanco Animal Health?

Summary

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. BBIO, RDY, AXSM, ELAN, and ARWR

How does Relay Therapeutics compare to BridgeBio Pharma?

Do analysts recommend RLAY or BBIO?

Is RLAY or BBIO more profitable?

Do institutionals & insiders have more ownership in RLAY or BBIO?

Which has more risk & volatility, RLAY or BBIO?

Which has preferable earnings and valuation, RLAY or BBIO?

Does the media favor RLAY or BBIO?

Summary

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, RLAY or RDY?

Which has better valuation & earnings, RLAY or RDY?

Is RLAY or RDY more profitable?

Do insiders & institutionals have more ownership in RLAY or RDY?

Do analysts recommend RLAY or RDY?

Does the media prefer RLAY or RDY?

Summary

How does Relay Therapeutics compare to Axsome Therapeutics?

Does the media favor RLAY or AXSM?

Which has preferable valuation and earnings, RLAY or AXSM?

Do insiders and institutionals believe in RLAY or AXSM?

Do analysts rate RLAY or AXSM?

Which has more risk & volatility, RLAY or AXSM?

Is RLAY or AXSM more profitable?

Summary

How does Relay Therapeutics compare to Elanco Animal Health?

Which has better valuation and earnings, ELAN or RLAY?

Which has more risk and volatility, ELAN or RLAY?

Do analysts rate ELAN or RLAY?

Is ELAN or RLAY more profitable?

Do institutionals and insiders have more ownership in ELAN or RLAY?

Does the media refer more to ELAN or RLAY?

Summary

How does Relay Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more volatility & risk, ARWR or RLAY?

Do analysts recommend ARWR or RLAY?

Do insiders & institutionals have more ownership in ARWR or RLAY?

Is ARWR or RLAY more profitable?

Does the media refer more to ARWR or RLAY?

Which has preferable valuation & earnings, ARWR or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools